Yes, targeting myeloid cells has shown promise in cancer therapy. Strategies include depleting MDSCs, reprogramming TAMs from a pro-tumor (M2) to an anti-tumor (M1) phenotype, and blocking the recruitment of myeloid cells to the tumor site. These approaches aim to reduce the immunosuppressive environment and enhance the efficacy of existing immunotherapies such as checkpoint inhibitors.
